Schuler M - Search Results

1

Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.

Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C, Schuler M. Wesarg E, et al. Among authors: schuler m. Int J Cancer. 2007 Dec 1;121(11):2387-94. doi: 10.1002/ijc.22977. Int J Cancer. 2007. PMID: 17688235

2

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

Kuball J, Wen SF, Leissner J, Atkins D, Meinhardt P, Quijano E, Engler H, Hutchins B, Maneval DC, Grace MJ, Fritz MA, Störkel S, Thüroff JW, Huber C, Schuler M. Kuball J, et al. Among authors: schuler m. J Clin Oncol. 2002 Feb 15;20(4):957-65. doi: 10.1200/JCO.2002.20.4.957. J Clin Oncol. 2002. PMID: 11844817 Clinical Trial.

3

The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases.

Milosevic J, Hoffarth S, Huber C, Schuler M. Milosevic J, et al. Among authors: schuler m. Oncogene. 2003 Oct 9;22(44):6852-6. doi: 10.1038/sj.onc.1206716. Oncogene. 2003. PMID: 14534531

4

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4.

Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR, Moehler M. Schimanski CC, et al. Among authors: schuler m. Br J Cancer. 2006 Jul 17;95(2):210-7. doi: 10.1038/sj.bjc.6603251. Epub 2006 Jul 4. Br J Cancer. 2006. PMID: 16819541 Free PMC article.

5

Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.

Hess G, Flohr T, Kolbe K, Bonn S, Schuler M, Derigs HG, Huber C. Hess G, et al. Among authors: schuler m. Ann Hematol. 2006 Nov;85(11):769-79. doi: 10.1007/s00277-006-0157-6. Epub 2006 Aug 1. Ann Hematol. 2006. PMID: 16896912 Clinical Trial.

6

Therapeutic targeting of apoptotic pathways in cancer.

Meiler J, Schuler M. Meiler J, et al. Among authors: schuler m. Curr Drug Targets. 2006 Oct;7(10):1361-9. doi: 10.2174/138945006778559175. Curr Drug Targets. 2006. PMID: 17073598 Review.

7

An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.

Marques CA, Hähnel PS, Wölfel C, Thaler S, Huber C, Theobald M, Schuler M. Marques CA, et al. Among authors: schuler m. Blood. 2008 Feb 1;111(3):1413-9. doi: 10.1182/blood-2007-05-089458. Epub 2007 Oct 30. Blood. 2008. PMID: 17971488 Free article.

8

Targeting AKT signaling sensitizes cancer to cellular immunotherapy.

Hähnel PS, Thaler S, Antunes E, Huber C, Theobald M, Schuler M. Hähnel PS, et al. Among authors: schuler m. Cancer Res. 2008 May 15;68(10):3899-906. doi: 10.1158/0008-5472.CAN-07-6286. Cancer Res. 2008. PMID: 18483275

9

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

Stolz C, Hess G, Hähnel PS, Grabellus F, Hoffarth S, Schmid KW, Schuler M. Stolz C, et al. Among authors: schuler m. Blood. 2008 Oct 15;112(8):3312-21. doi: 10.1182/blood-2007-11-124487. Epub 2008 Aug 8. Blood. 2008. PMID: 18689543 Free article.

10

ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer.

Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, Schormann W, Selinski S, Freis E, Schwender H, Brulport M, Ickstadt K, Rahnenführer J, Maccoux L, West J, Kölbl H, Schuler M, Hengstler JG. Petry IB, et al. Among authors: schuler m. Clin Cancer Res. 2010 Jan 15;16(2):451-60. doi: 10.1158/1078-0432.CCR-09-1617. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068093

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,074 results

Search Page

Filters